11
NEWS
this ambitious pledge will be pivotal
in accelerating research towards a
cure. Diabetes UK and the Bukhman
Foundation are united by a shared
mission to drive excellence in type
1 research, and we are proud to be
partnering to fund cutting-edge
studies into the triggers of the
condition in children. We hope this
vital research will help prevent type 1
diabetes for future generations."
Breakthrough T1D
The donation given to the
Breakthrough T1D Barbara Dewey
Cammett Center of Excellence in
New England will support innovative
research into gene-edited, labgrown
islets, insulin-producing
cells that can be transplanted
into patients without the need for
powerful immunosuppressive drugs.
This work is central to making cell
therapy cures both safer and more
widely accessible. In people with
T1D, the immune system mistakenly
attacks and destroys the pancreas's
beta cells, which are responsible
for producing insulin. Cell therapies
aim to cure T1D by replacing these
destroyed cells with healthy, insulinproducing
ones and ensuring they
are protected so they can survive
and function long-term. The Centre's
mission is to develop methods for
growing these cells in the laboratory
and finding ways to shield them
inside the body without requiring
lifelong immunosuppression.
Aaron Kowalski, Breakthrough
T1D CEO in the US, commented,
"Breakthrough T1D is driving the
development and delivery of cures
to people with T1D. The Bukhman
Foundation's pledge will help us
further accelerate the amazing
progress we are seeing in type 1
diabetes cell therapy development.
These cures are truly a matter of
when, not if. With generous support
from people like Anastasia and Igor,
we will make cell therapy cures for
T1D a reality, sooner."
Karen Addington, CEO
Breakthrough T1D UK, "On behalf of
the 9 million people living with type
1 diabetes the world over, we want to
thank the Bukhman family for their
Foundation's £100 million historic
commitment. They have turned their
own experience of type 1 diabetes
into a catalyst for change: to enable
the world's greatest scientists to
go further and faster in advancing
type 1 diabetes medical research
breakthroughs. The keys to cures lie
in cellular therapies, creating insulin
producing beta cells and reducing
immunosuppression. This gift will
help unlock those cures."
www.bukhmanfoundation.org
A natural home
A renowned expert in diabetes
research will lead the future of
research dissemination in Diabetes
UK's flagship journal.
Professor Noel Morgan,
Emeritus professor of Endocrine
Pharmacology at the University of
Exeter Medical School, will assume
his role as Editor-in-Chief of Diabetic
Medicine from Tuesday 1 July 2025.
Diabetes UK's journal Diabetic
Medicine focuses on disseminating
research on all aspects of diabetes to
improve the management of people
with the condition. Professor Morgan
takes over from Professor Nick Oliver
of Imperial College London who
led the editorial team of Diabetic
Medicine journal in the last four
years.
Prof Morgan's 45-year research
career has yielded significant
breakthrough in Type 1 diabetes
treatment. This includes the
emergence of new clinical trials of
anti-viral agents in treating viral
infection after diabetes occurs in
children.
He says, "I'm honoured and
delighted to have been offered the
opportunity to serve as the next
Editor-in-Chief of Diabetic Medicine.
Among healthcare professionals
journal is recognised as a jewel in
the crown of Diabetes UK, and it
is a privilege to be entrusted to
lead its exceptional editorial team.
I'm excited to ensure that Diabetic
Medicine is seen as a natural home
for papers reporting the highest
quality and most impactful research
in the diabetes field across the globe".
Dedicated NHS Diabetes Advice helpline
0345 123 2399